Ribupatide
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
Fujian Shengdi Pharmaceutical Co · Phase 2 · Active, not recruiting · Enrollment 264
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Ribupatide: Dose 1 | n/r | n/r | n/r | n/r | n/r |
| Ribupatide: Dose 2 | n/r | n/r | n/r | n/r | n/r |
| Ribupatide: Dose 3 | n/r | n/r | n/r | n/r | n/r |
| Ribupatide: Dose 4 | n/r | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.